You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMannitol
Accession NumberDB00742  (APRD01083, EXPT02246)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid.
Structure
Thumb
Synonyms
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
D-(-)-Mannitol
D-Mannitol
e 421
e-421
e421
Fraxinine
Manitol
Manna Sugar
Mannit
Mannite
Mannitol
Mannitolum
Osmitrol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis Pharmaceuticals Limited2012-04-13Not applicableEu
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis Pharmaceuticals Limited2012-04-13Not applicableEu
MannitolInjection, solution20 g/100mLIntravenousHospira, Inc.1987-01-08Not applicableUs
MannitolIrrigant5 g/100mLIrrigationB. Braun Medical Inc.1978-02-10Not applicableUs
MannitolInjection, solution20 g/100mLIntravenousB. Braun Medical Inc.1993-07-26Not applicableUs
MannitolInjection, solution5 g/100mLIntravenousHospira, Inc.1987-01-082016-11-16Us
MannitolInjection, solution12.5 g/50mLIntravenousHospira, Inc.1967-12-22Not applicableUs
MannitolInjection, solution10 g/100mLIntravenousHospira, Inc.1987-01-082016-11-16Us
MannitolInjection, solution15 g/100mLIntravenousHospira, Inc.1987-01-08Not applicableUs
Mannitol 20%Solution200 mgIntravenousHospira Healthcare Corporation1963-12-31Not applicableCanada
Mannitol 25%Solution250 mgIntravenousHospira Healthcare Corporation1970-12-31Not applicableCanada
Mannitol Inj 10% AbbovacLiquid100 mgIntravenousAbbott Laboratories, Limited1963-12-311999-08-09Canada
Mannitol Inj 25%Liquid250 mgIntravenousAstra Pharma Inc.1987-12-312000-07-20Canada
Mannitol Inj 25%Liquid250 mgIntravenousInternational Medication Systems Ltd.1971-12-311997-08-15Canada
Mannitol Inj 5% AbbovacLiquid50 mgIntravenousAbbott Laboratories, Limited1963-12-311999-08-09Canada
Mannitol InjectionSolution250 mgIntravenousFresenius Kabi Canada Ltd2002-04-09Not applicableCanada
OsmitrolInjection, solution20 g/100mLIntravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
OsmitrolInjection, solution5 g/100mLIntravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
OsmitrolInjection, solution10 g/100mLIntravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
OsmitrolInjection, solution15 g/100mLIntravenousBaxter Healthcare Corporation1964-06-08Not applicableUs
Osmitrol 10% Inj USPLiquid10 gIntravenousBaxter Corporation1989-12-31Not applicableCanada
Osmitrol 20% Inj USPSolution20 gIntravenousBaxter Corporation1989-12-31Not applicableCanada
Resectisol (5% Mannitol Irrigation)Liquid5 %IrrigationB. Braun Medical Inc1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MannitolInjection, solution250 mg/mLIntravenousAmerican Regent, Inc.1990-09-30Not applicableUs
MannitolInjection, solution250 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
MannitolInjection, solution12.5 g/50mLIntravenousCardinal Health2010-02-01Not applicableUs
MannitolInjection, solution250 mg/mLIntravenousFresenius Kabi USA, LLC2000-03-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnolAstar
AridolPharmaxis
BronchitolPharmaxis
DeltamannitDeltaSelect
DemanitolMedifarma
DiurecideLusa
IsotolNot Available
ManicolNot Available
ManitPliva
Manitol MeinFresenius
ManitonNot Available
MannigenNot Available
MannisolHuman Co. Ltd.
Mannisol ATeva
MannitNot Available
Mannit-LösungSerag-Wiessner
Mannite ActipharmActipharm
OsmofundinB. Braun
OsmohalePharmaxis
OsmosolBeximco
OsmosterilFresenius
ResectisolB. Braun
Brand mixtures
NameLabellerIngredients
Additive Solution Sodium Adenine Glucose Mannitol (SAGM)Maco Pharma
Cystosol W 3% HexitolsBaxter Corporation
Leukosep - Solx A Additive SolutionHaemonetics Manufacturing Inc
Leukotrap Solx A AdditiveHaemonetics Manufacturing Inc
Sag-MHaemonetics Corporation
Sorbitol Mannitol IrrigationHospira Healthcare Corporation
Sorbitol-mannitolHospira, Inc.
SaltsNot Available
Categories
UNII3OWL53L36A
CAS number69-65-8
WeightAverage: 182.1718
Monoisotopic: 182.07903818
Chemical FormulaC6H14O6
InChI KeyFBPFZTCFMRRESA-KVTDHHQDSA-N
InChI
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
IUPAC Name
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
SMILES
OC[C@@H](O)[C@@H](O)[[email protected]](O)[[email protected]](O)CO
Pharmacology
IndicationUsed for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.
Structured Indications
PharmacodynamicsChemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitol is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitol is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement.
Mechanism of actionMannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).
Related Articles
AbsorptionApproximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.
Volume of distributionNot Available
Protein bindingNone
Metabolism

Mannitol is metabolized only slightly, if at all, to glycogen in the liver.

SubstrateEnzymesProduct
Mannitol
Not Available
GlycogenDetails
Route of eliminationIt is rapidly excreted in the urine.
Half life100 minutes
ClearanceNot Available
ToxicityLD50=1700 mg/kg (rat oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.Approved
AcetaminophenThe serum concentration of Mannitol can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Acetazolamide.Approved, Vet Approved
AclarubicinMannitol may increase the nephrotoxic activities of Aclarubicin.Investigational
AfatinibThe serum concentration of Mannitol can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Mannitol can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.Approved
AldosteroneThe serum concentration of Mannitol can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Mannitol can be increased when it is combined with Alectinib.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mannitol.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Mannitol is combined with Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Mannitol.Experimental, Illicit
AmantadineThe serum concentration of Mannitol can be increased when it is combined with Amantadine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Mannitol is combined with Amifostine.Approved, Investigational
AmikacinMannitol may increase the nephrotoxic activities of Amikacin.Approved, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Mannitol.Approved
Aminohippuric acidThe serum concentration of Mannitol can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Mannitol can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Mannitol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Mannitol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Mannitol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Mannitol is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Mannitol can be decreased when it is combined with Amprenavir.Approved
AmrubicinMannitol may increase the nephrotoxic activities of Amrubicin.Approved, Investigational
AmsacrineThe serum concentration of Mannitol can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Mannitol is combined with Amyl Nitrite.Approved
annamycinMannitol may increase the nephrotoxic activities of annamycin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Mannitol is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Mannitol is combined with Apraclonidine.Approved
ApramycinMannitol may increase the nephrotoxic activities of Apramycin.Experimental, Vet Approved
ArbekacinMannitol may increase the nephrotoxic activities of Arbekacin.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Mannitol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Mannitol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Mannitol is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe serum concentration of Mannitol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Mannitol can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Mannitol.Approved
AtorvastatinThe serum concentration of Mannitol can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Mannitol can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Mannitol is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Mannitol can be increased when it is combined with Azithromycin.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Mannitol.Experimental
BarbitalBarbital may increase the hypotensive activities of Mannitol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mannitol.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mannitol.Approved
BenzocaineThe serum concentration of Mannitol can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Mannitol can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mannitol.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Mannitol.Experimental, Illicit, Withdrawn
BiperidenThe serum concentration of Mannitol can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mannitol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Mannitol is combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Mannitol can be increased when it is combined with Bosutinib.Approved
BretyliumThe risk or severity of adverse effects can be increased when Mannitol is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Mannitol.Approved
BromocriptineThe serum concentration of Mannitol can be increased when it is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Mannitol is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Mannitol is combined with Bupivacaine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mannitol.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Mannitol can be increased when it is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mannitol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Mannitol can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Mannitol can be increased when it is combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Captopril.Approved
CarbamazepineThe serum concentration of Mannitol can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Mannitol is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Mannitol.Illicit, Vet Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Mannitol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Mannitol is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Mannitol can be increased when it is combined with Caspofungin.Approved
ChloroquineThe serum concentration of Mannitol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Mannitol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Mannitol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Mannitol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mannitol.Approved
CholesterolThe serum concentration of Mannitol can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Mannitol can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Mannitol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Mannitol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Mannitol can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Mannitol can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Mannitol is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Mannitol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Mannitol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Mannitol.Approved
ClotrimazoleThe serum concentration of Mannitol can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Mannitol is combined with Clozapine.Approved
CobicistatThe serum concentration of Mannitol can be increased when it is combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mannitol.Approved, Illicit
ColchicineThe serum concentration of Mannitol can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Mannitol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Mannitol is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Mannitol can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Mannitol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Mannitol can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaclatasvirThe serum concentration of Mannitol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Mannitol can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Dapagliflozin.Approved
DasatinibThe serum concentration of Mannitol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinMannitol may increase the nephrotoxic activities of Daunorubicin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Mannitol is combined with Desflurane.Approved
DesipramineThe serum concentration of Mannitol can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Mannitol can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Mannitol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mannitol.Approved, Vet Approved
DextromethorphanThe serum concentration of Mannitol can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Mannitol.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mannitol.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Mannitol.Approved
DiclofenacThe serum concentration of Mannitol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Diclofenamide.Approved
DigoxinThe serum concentration of Mannitol can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Mannitol.Approved, Illicit
DihydroergotamineThe serum concentration of Mannitol can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Mannitol.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Mannitol.Experimental, Illicit
DihydrostreptomycinMannitol may increase the nephrotoxic activities of Dihydrostreptomycin.Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Mannitol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Mannitol is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Mannitol.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Mannitol is combined with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.Approved
DoxepinThe serum concentration of Mannitol can be increased when it is combined with Doxepin.Approved
DoxorubicinMannitol may increase the nephrotoxic activities of Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Mannitol.Investigational
DronabinolThe serum concentration of Mannitol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Mannitol can be increased when it is combined with Dronedarone.Approved
DuloxetineMannitol may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Mannitol can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Mannitol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mannitol.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Mannitol is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Mannitol can be increased when it is combined with Enzalutamide.Approved
EpirubicinMannitol may increase the nephrotoxic activities of Epirubicin.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Mannitol.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Mannitol is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Eprosartan.Approved
ErgonovineThe serum concentration of Mannitol can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Mannitol can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Mannitol can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Mannitol.Approved
EstramustineThe serum concentration of Mannitol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Mannitol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Mannitol can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Mannitol is combined with Etacrynic acid.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Mannitol.Approved, Illicit
EtoposideThe serum concentration of Mannitol can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Mannitol.Illicit, Vet Approved
EtravirineThe serum concentration of Mannitol can be increased when it is combined with Etravirine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Mannitol is combined with Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mannitol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Mannitol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Mannitol can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Mannitol can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Mannitol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Mannitol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Mannitol can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Mannitol can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Mannitol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.Approved
FramycetinMannitol may increase the nephrotoxic activities of Framycetin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Mannitol.Approved, Vet Approved
GefitinibThe serum concentration of Mannitol can be increased when it is combined with Gefitinib.Approved, Investigational
GeneticinMannitol may increase the nephrotoxic activities of Geneticin.Experimental
GenisteinThe serum concentration of Mannitol can be increased when it is combined with Genistein.Investigational
GentamicinMannitol may increase the nephrotoxic activities of Gentamicin.Approved, Vet Approved
GENTAMICIN C1AMannitol may increase the nephrotoxic activities of GENTAMICIN C1A.Experimental
GlyburideThe serum concentration of Mannitol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Mannitol can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Mannitol can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Mannitol can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Mannitol is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Mannitol can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Mannitol is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Mannitol.Approved, Illicit
HexobarbitalHexobarbital may increase the hypotensive activities of Mannitol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mannitol.Approved, Illicit
HydrocortisoneThe serum concentration of Mannitol can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Mannitol is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mannitol.Approved, Illicit
Hygromycin BMannitol may increase the nephrotoxic activities of Hygromycin B.Vet Approved
IdarubicinMannitol may increase the nephrotoxic activities of Idarubicin.Approved
IdelalisibThe serum concentration of Mannitol can be increased when it is combined with Idelalisib.Approved
IloprostThe risk or severity of adverse effects can be increased when Mannitol is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Mannitol can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Mannitol can be increased when it is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Mannitol is combined with Indapamide.Approved
IndinavirThe serum concentration of Mannitol can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Mannitol can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Mannitol is combined with Indoramin.Withdrawn
INNO-206Mannitol may increase the nephrotoxic activities of INNO-206.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Mannitol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Mannitol is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Mannitol is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Mannitol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Mannitol.Approved
ItraconazoleThe serum concentration of Mannitol can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mannitol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Mannitol can be increased when it is combined with Ivermectin.Approved, Vet Approved
KanamycinMannitol may increase the nephrotoxic activities of Kanamycin.Approved, Vet Approved
KetamineThe serum concentration of Mannitol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Mannitol.Approved
KetoconazoleThe serum concentration of Mannitol can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mannitol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Lacidipine.Approved
LansoprazoleThe serum concentration of Mannitol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Mannitol can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Mannitol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Mannitol is combined with Levobupivacaine.Approved
LevodopaMannitol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Mannitol can be increased when it is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Mannitol.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mannitol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Mannitol is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Mannitol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Mannitol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Mannitol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Mannitol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mannitol.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Mannitol.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Mannitol is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Mannitol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Mannitol can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Mannitol can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Mannitol can be increased when it is combined with Loratadine.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.Approved
LovastatinThe serum concentration of Mannitol can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Mannitol can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Mannitol can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Mannitol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mannitol.Approved
MefloquineThe serum concentration of Mannitol can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Mannitol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Mannitol can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mannitol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Mannitol.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Mannitol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Mannitol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mannitol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Mannitol is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Mannitol.Approved
MetipranololThe risk or severity of adverse effects can be increased when Mannitol is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mannitol.Approved, Investigational
MetrizamideMannitol may increase the nephrotoxic activities of Metrizamide.Approved
MibefradilThe serum concentration of Mannitol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Mannitol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Mannitol can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Mannitol can be decreased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Mannitol.Approved
MitomycinThe serum concentration of Mannitol can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Mannitol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mannitol.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mannitol.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Mannitol is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Mannitol is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Mannitol is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mannitol.Approved
NaltrexoneThe serum concentration of Mannitol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Mannitol can be increased when it is combined with Naringenin.Experimental
NeamineMannitol may increase the nephrotoxic activities of Neamine.Experimental
NebivololThe risk or severity of adverse effects can be increased when Mannitol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Mannitol can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Mannitol can be decreased when it is combined with Nelfinavir.Approved
NeomycinMannitol may increase the nephrotoxic activities of Neomycin.Approved, Vet Approved
NeostigmineThe serum concentration of Mannitol can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Mannitol is combined with Nesiritide.Approved, Investigational
NetilmicinMannitol may increase the nephrotoxic activities of Netilmicin.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Mannitol.Approved
NicorandilNicorandil may increase the hypotensive activities of Mannitol.Approved
NifedipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Nifedipine.Approved
NilotinibThe serum concentration of Mannitol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Mannitol is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mannitol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Mannitol.Approved
NitrazepamThe serum concentration of Mannitol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Mannitol can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Mannitol is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Mannitol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Mannitol.Approved
NorethisteroneThe serum concentration of Mannitol can be decreased when it is combined with Norethisterone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Mannitol.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Mannitol is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mannitol.Approved, Investigational
OmeprazoleThe serum concentration of Mannitol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Mannitol.Approved, Illicit
OxprenololThe risk or severity of adverse effects can be increased when Mannitol is combined with Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mannitol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Mannitol.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Mannitol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Mannitol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Mannitol can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Mannitol can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.Approved
ParomomycinMannitol may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
ParoxetineThe serum concentration of Mannitol can be increased when it is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Mannitol is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mannitol.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Mannitol.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mannitol.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Mannitol is combined with Phenelzine.Approved
PhenobarbitalThe serum concentration of Mannitol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Mannitol is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Mannitol is combined with Phentolamine.Approved
PimozideThe serum concentration of Mannitol can be increased when it is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Mannitol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Mannitol is combined with Pipamperone.Approved
PirarubicinMannitol may increase the nephrotoxic activities of Pirarubicin.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Mannitol.Investigational
Platelet Activating FactorThe serum concentration of Mannitol can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinMannitol may increase the nephrotoxic activities of Plicamycin.Approved, Withdrawn
PonatinibThe serum concentration of Mannitol can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Mannitol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Mannitol is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Mannitol can be increased when it is combined with Pravastatin.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Mannitol.Approved
PrednisoneThe serum concentration of Mannitol can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Mannitol.Approved, Vet Approved
ProbenecidThe serum concentration of Mannitol can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Mannitol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Mannitol can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Mannitol can be increased when it is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Mannitol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Mannitol.Approved, Investigational
ProtriptylineThe serum concentration of Mannitol can be increased when it is combined with Protriptyline.Approved
PuromycinMannitol may increase the nephrotoxic activities of Puromycin.Experimental
QuercetinThe serum concentration of Mannitol can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Mannitol is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Mannitol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Mannitol is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Mannitol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Mannitol can be increased when it is combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mannitol.Approved
RanitidineThe serum concentration of Mannitol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Mannitol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Mannitol is combined with Rasagiline.Approved
ReboxetineThe serum concentration of Mannitol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Mannitol can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mannitol.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mannitol.Approved
RibostamycinMannitol may increase the nephrotoxic activities of Ribostamycin.Approved
RifampicinThe serum concentration of Mannitol can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Mannitol can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Mannitol is combined with Riociguat.Approved
RisperidoneMannitol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Mannitol can be decreased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Mannitol can be increased when it is combined with Rolapitant.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Mannitol is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Mannitol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Mannitol is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Mannitol is combined with Sacubitril.Approved
SaquinavirThe serum concentration of Mannitol can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Mannitol can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Mannitol.Approved, Vet Approved
SelegilineThe serum concentration of Mannitol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Mannitol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Mannitol is combined with Sevoflurane.Approved, Vet Approved
SimeprevirThe serum concentration of Mannitol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Mannitol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Mannitol can be decreased when it is combined with Sirolimus.Approved, Investigational
SisomicinMannitol may increase the nephrotoxic activities of Sisomicin.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Mannitol is combined with Sodium Nitrite.Approved
SorafenibThe serum concentration of Mannitol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.Approved
SP1049CMannitol may increase the nephrotoxic activities of SP1049C.Investigational
SpectinomycinMannitol may increase the nephrotoxic activities of Spectinomycin.Approved, Vet Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.Approved
St. John's WortThe serum concentration of Mannitol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Mannitol can be increased when it is combined with Staurosporine.Experimental
StreptokinaseThe risk or severity of adverse effects can be increased when Mannitol is combined with Streptokinase.Approved
StreptomycinMannitol may increase the nephrotoxic activities of Streptomycin.Approved, Vet Approved
StreptozocinMannitol may increase the nephrotoxic activities of Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.Approved, Investigational
SulfinpyrazoneThe serum concentration of Mannitol can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Mannitol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Mannitol can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Mannitol can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Mannitol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Mannitol can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Mannitol is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mannitol.Approved
Taurocholic AcidThe serum concentration of Mannitol can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe risk or severity of adverse effects can be increased when Mannitol is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Mannitol can be increased when it is combined with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.Approved
TerfenadineThe serum concentration of Mannitol can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Mannitol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Mannitol can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Mannitol is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Mannitol.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Mannitol.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Mannitol is combined with Thioridazine.Approved
TicagrelorThe serum concentration of Mannitol can be increased when it is combined with Ticagrelor.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Mannitol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Mannitol.Approved
TobramycinMannitol may increase the nephrotoxic activities of Tobramycin.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Mannitol is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Mannitol is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Mannitol can be increased when it is combined with Tolvaptan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mannitol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mannitol.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Mannitol is combined with Tranylcypromine.Approved
TrazodoneThe serum concentration of Mannitol can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Mannitol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Mannitol.Approved
TrifluoperazineThe serum concentration of Mannitol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Mannitol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Mannitol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Mannitol can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Mannitol can be increased when it is combined with Troleandomycin.Approved
ValrubicinMannitol may increase the nephrotoxic activities of Valrubicin.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mannitol.Approved, Investigational
VenlafaxineThe serum concentration of Mannitol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Mannitol.Approved
VinblastineThe serum concentration of Mannitol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Mannitol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Mannitol can be increased when it is combined with Vinorelbine.Approved, Investigational
ZimelidineThe serum concentration of Mannitol can be increased when it is combined with Zimelidine.Withdrawn
ZorubicinMannitol may increase the nephrotoxic activities of Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Walter M. Kruse, “Process for preparing mannitol from glucose.” U.S. Patent US4029878, issued August, 1956.

US4029878
General References
  1. Cruz J, Minoja G, Okuchi K: Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: a randomized trial. Neurosurgery. 2001 Oct;49(4):864-71. [PubMed:11564247 ]
  2. Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial. Neurosurgery. 2002 Sep;51(3):628-37; discussion 637-8. [PubMed:12188940 ]
  3. Cruz J, Minoja G, Okuchi K, Facco E: Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg. 2004 Mar;100(3):376-83. [PubMed:15035271 ]
  4. Roberts I, Smith R, Evans S: Doubts over head injury studies. BMJ. 2007 Feb 24;334(7590):392-4. [PubMed:17322250 ]
  5. Wakai A, Roberts I, Schierhout G: Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001049. [PubMed:16235278 ]
  6. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187 ]
External Links
ATC CodesB05BC01B05CX04A06AD16R05CB16
AHFS Codes
  • 36:68.00
  • 40:28.12
  • 40:36.00
PDB Entries
FDA labelDownload (50 KB)
MSDSDownload (72.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6525
Blood Brain Barrier-0.5997
Caco-2 permeable-0.8958
P-glycoprotein substrateNon-substrate0.662
P-glycoprotein inhibitor INon-inhibitor0.9535
P-glycoprotein inhibitor IINon-inhibitor0.9551
Renal organic cation transporterNon-inhibitor0.9252
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.878
CYP450 3A4 substrateNon-substrate0.7431
CYP450 1A2 substrateNon-inhibitor0.824
CYP450 2C9 inhibitorNon-inhibitor0.9419
CYP450 2D6 inhibitorNon-inhibitor0.9412
CYP450 2C19 inhibitorNon-inhibitor0.9232
CYP450 3A4 inhibitorNon-inhibitor0.9402
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.958
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7823
BiodegradationReady biodegradable0.8595
Rat acute toxicity1.1260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9709
hERG inhibition (predictor II)Non-inhibitor0.9329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • B braun medical inc
  • Hospira inc
  • Miles laboratories inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • International medication system
  • Luitpold pharmaceuticals inc
  • Merck and co inc
  • Watson laboratories inc
  • Baxter healthcare corp
Packagers
Dosage forms
FormRouteStrength
CapsuleRespiratory (inhalation)40 mg
LiquidIrrigation
SolutionIntravenous
Injection, solutionIntravenous12.5 g/50mL
Injection, solutionIntravenous250 mg/mL
IrrigantIrrigation5 g/100mL
SolutionIntravenous200 mg
SolutionIntravenous250 mg
LiquidIntravenous100 mg
LiquidIntravenous250 mg
LiquidIntravenous50 mg
Injection, solutionIntravenous10 g/100mL
Injection, solutionIntravenous15 g/100mL
Injection, solutionIntravenous20 g/100mL
Injection, solutionIntravenous5 g/100mL
LiquidIntravenous10 g
SolutionIntravenous20 g
LiquidIrrigation5 %
SolutionUnknown
SolutionIrrigation
IrrigantUrethral
Prices
Unit descriptionCostUnit
Osmitrol 20% iv solution0.15USD ml
Osmitrol 10% iv solution0.07USD ml
Osmitrol 15% iv solution0.07USD ml
Mannitol powder0.05USD g
Mannitol 15% iv solution0.04USD ml
Mannitol 20% iv solution0.04USD ml
Mannitol 25% vial0.03USD ml
Osmitrol 5% iv solution0.03USD ml
Mannitol 10% iv solution0.02USD ml
Mannitol 5% iv solution0.02USD ml
Resectisol 5% solution0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point168 °CPhysProp
boiling point290-295 °C at 3.50E+00 mm HgPhysProp
water solubility2.16E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-3.10HANSCH,C ET AL. (1995)
Caco2 permeability-6.21ADME Research, USCD
pKa13.5 (at 25 °C)BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility229.0 mg/mLALOGPS
logP-2.7ALOGPS
logP-3.7ChemAxon
logS0.1ALOGPS
pKa (Strongest Acidic)12.59ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area121.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity38.4 m3·mol-1ChemAxon
Polarizability16.82 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.14 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (6 TMS)splash10-0ktb-0931000000-b481d576c5f24dd1b1d5View in MoNA
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-066s-0942000000-20043a375d72ca08dce9View in MoNA
GC-MSGC-MS Spectrum - GC-MS (6 TMS)splash10-066r-1974000000-38a4beaca17ab8c750b6View in MoNA
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-014j-9600000000-26f4335f7ef7c81ca261View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-066r-9000000000-73db1fbd51fb8c061becView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-05mo-9000000000-45a4dea1d21286c4b8daView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negativesplash10-0089-6900000000-961d76d6550bc342ffa1View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassSugar alcohols
Direct ParentSugar alcohols
Alternative Parents
Substituents
  • Sugar alcohol
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • Hydrocarbon derivative
  • Primary alcohol
  • Alcohol
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Enzymes

Kind
Protein
Organism
Pseudomonas fluorescens
Pharmacological action
unknown
Actions
substrate
General Function:
Nucleotide binding
Specific Function:
Not Available
Gene Name:
mtlD
Uniprot ID:
O08355
Molecular Weight:
54497.41 Da
References
  1. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23